These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38826625)

  • 1. Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction.
    Tanninen TH; Pelkonen AS; Malmberg LP; Mäkelä MJ
    J Allergy Clin Immunol Glob; 2024 Aug; 3(3):100268. PubMed ID: 38826625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy.
    Svedsater H; Stynes G; Wex J; Frith L; Leather D; Castelnuovo E; Detry M; Berry S
    Asthma Res Pract; 2016; 2():4. PubMed ID: 27965772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vilanterol and fluticasone furoate for asthma.
    Dwan K; Milan SJ; Bax L; Walters N; Powell C
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
    Rodrigo GJ; Plaza V
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):565-70. PubMed ID: 27117053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Haruta Y; Hozawa M
    Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial.
    Furuhashi K; Fujisawa T; Hashimoto D; Kamiya Y; Yasui H; Karayama M; Suzuki Y; Hozumi H; Enomoto N; Nakamura Y; Inui N; Suda T
    J Asthma Allergy; 2019; 12():253-261. PubMed ID: 31571932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
    Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database.
    Atsuta R; Takai J; Mukai I; Kobayashi A; Ishii T; Svedsater H
    Pulm Ther; 2018 Dec; 4(2):135-147. PubMed ID: 32026395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
    Woodcock A; Bleecker ER; Lötvall J; O'Byrne PM; Bateman ED; Medley H; Ellsworth A; Jacques L; Busse WW
    Chest; 2013 Oct; 144(4):1222-1229. PubMed ID: 23846316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.
    Martin N; Weiler JM; Pearlman D; Jacques L; Nunn C; Forth R; West S; Dunn K; O'Byrne PM
    J Asthma; 2020 Apr; 57(4):431-440. PubMed ID: 30795705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.